Industries > Pharma > Lyophilisation for Pharmaceuticals: Products and Services 2014-2024

Lyophilisation for Pharmaceuticals: Products and Services 2014-2024

& Future Prospects for Leading Companies

PUBLISHED: 11 February 2014
PAGES: 254
PRODUCT CODE:

Clear
WOOCS 2.2.1

Lyophilisation for pharmaceuticals – discover trends and segments with highest revenue potential

What are the commercial prospects for pharmaceutical freeze-drying? Visiongain’s brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our new study lets you assess projected sales at world market, submarket and national level to 2024. You will see financial results, interviews, trends, opportunities, and revenue predictions. In our investigation you also see qualitative analyses, news, R&D and business developments. Also, you see qualitative analyses (SWOT, PESTEL and Porter’s Five Forces).

Our 254 page report provides 143 tables, charts, and graphs. Read the full transcripts of three exclusive expert opinion interviews from leading industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
– Dr. Davide Fissore, Professor of Advanced Process Control, Food Processing Technologies and Data Driven Modelling, Politecnico di Torino
– Dr. Tudor Arvinte, CEO, Therapeomic Inc and Professor at University of Geneva (Switzerland), Department of Pharmaceutics and Biopharmaceutics
– Dr. Matthew Brown, Development Scientist, Genzyme

You will find prospects for freeze drying submarkets and therapeutic applications

In addition to analyses of the overall world market, you will see revenue forecasting of four world-level submarkets to 2024:
• cGMP lyophilisers
• Laboratory lyophilisers
• Lyophilisation services
• Others

Also, you will see how nine drug classes using freeze drying technology will perform to 2024:
• Therapeutic monoclonal antibodies (mAbs)
• Insulins
• Erythropoietins
• Interferons
• G-CSF agents
• Recombinant coagulation factors
• Biosimilars
• Vaccines
• Other therapeutic proteins

Our investigation shows business research and analysis with individual revenue forecasts and discussions. Use our predictions to help expand your business and give you more influence. You will receive the forecasting leaders need.

What are the prospects in leading regions and countries?

There are many commercial opportunities for lyophilisation technology and services in developed and developing countries. Our investigation gives you multi-level business research and analysis with sales forecast. You see how the industry and market can perform from 2014 to 2024.

In our study you will find individual revenue forecasts to 2024 for 14 national markets:
•    US
•    Japan
•    Germany
•    France
•    Italy
•    Spain
•    UK
•    China
•    India
•    Russia
•    Brazil
•    Turkey
•    Mexico
•    South Korea
•    RoW

In particular, some Asia Pacific regions will show high growth. New biological drugs and vaccines will benefit regional and national markets for those pharmaceutical drying technologies.

Leading companies and potential for market growth

Overall world revenue for the lyophilisation market will reach $3.09bn in 2014, our work forecasts. We predict strong revenue growth from 2014 to 2024. Our work shows you what services and organisations hold greatest potential. See profiles of 7 leading companies, including these:
•    SP Scientific
•    GEA Pharma Systems
•    IlShinBioBase
•    Vetter Pharma-Fertigung
•    Labconco Corporation
•    Boehringer Ingelheim
•    IMA Life

In general, a company profile gives you the following information
•    Discussion of a company’s activities and outlook
•    Recent financial results
•    Assessment of recent developments – mergers and acquisitions (M&A) and collaborations

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

Prominent Issues affecting the industry and market

Our study lets you assess industry trends and outlooks. You will find discussions, including qualitative analyses:
•    Increasing demand for parenteral drugs
•    Growing markets for biopharmaceutical products
•    Preparation, protection and storage of labile and heat-sensitive drugs
•    Injectable solutions, therapeutic proteins, peptides, vaccines and other aspects of biopharmaceutical production
•    Emerging technologies such as controlled ice nucleation and novel PAT tools

You will see discussions of technological, commercial, and economic matters, with emphasis on organisations developing technologies and services.

How the Lyophilisation for Pharmaceuticals: Products and Services 2014-2024 & Future Market Prospects for Leading Companies report helps you

In summary, our 254 page report gives you the following knowledge:
•    Revenues forecasts to 2024 for the overall world market and 4 submarkets – discover the industry’s prospects, finding promising places for investments and revenues
•    Assessment of 7 leading companies, and others, discovering activities and outlooks
•    Market forecasting to 2024 for 14 national markets – US, Japan, Germany, France, UK, Italy Spain, Brazil, Russia, India, China, Mexico, Turkey, South Korea and RoW
•    View opinions from our survey, seeing interviews with authorities
•    Investigation of competition and opportunities influencing sales
•    Discussion of what stimulates and restrains the industry and market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for lyophilisation for pharmaceuticals. You will find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

To view free sample pages of this report please click here

Download sample pages

Complete the form below to download your free sample pages for Lyophilisation for Pharmaceuticals: Products and Services 2014-2024


Download sample pages

Complete the form below to download your free sample pages for Lyophilisation for Pharmaceuticals: Products and Services 2014-2024


Latest Pharma news

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

READ

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

READ

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

READ

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

READ

Categories

Category